ArticleEuropean journal of drug metabolism and pharmacokinetics2020
Folate-Gold-Bilirubin Nanoconjugate Induces Apoptotic Death in Multidrug-Resistant Oral Carcinoma Cells.
Article in European journal of drug metabolism and pharmacokinetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Recent Advances in Nanocarrier-mediated Combination Drug Therapy for Tackling Solid-resistant Tumors.Current drug delivery · 2026Review
- Innovative nanoparticle strategies for treating oral cancers.Medical oncology (Northwood, London, England) · 2025Review
- Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer.International journal of molecular sciences · 2024Review
- Nano-Drug Delivery Systems in Oral Cancer Therapy: Recent Developments and Prospective.Pharmaceutics · 2023Review
- Influencing factors of anthracycline-induced subclinical cardiotoxicity in acute leukemia patients.BMC cancer · 2023Observational
- Toward nanotechnology-enabled application of bilirubin in the treatment and diagnosis of various civilization diseases.Materials today. Bio · 2023Review
- Therapeutic potential of pyrrole and pyrrolidine analogs: an update.Molecular diversity · 2022Review
- Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer.Journal of nanobiotechnology · 2022Review
- Current trends of targeted therapy for oral squamous cell carcinoma.Journal of cancer research and clinical oncology · 2022Review
- Gold nanomaterials for oral cancer diagnosis and therapy: Advances, challenges, and prospects.Materials today. Bio · 2022Article
- Bilirubin Improves Gap Junction to Alleviate Doxorubicin-Induced Cardiotoxicity by Regulating AMPK-Axl-SOCS3-Cx43 Axis.Frontiers in pharmacology · 2022Article
- Mastoparan, a Peptide Toxin from Wasp Venom Conjugated Fluvastatin Nanocomplex for Suppression of Lung Cancer Cell Growth.Polymers · 2021Article
- Nanoparticles in Dentistry: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Can bilirubin nanomedicine become a hope for the management of COVID-19?Medical hypotheses · 2021Article
- Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- Nanoparticles for Oral Cancer Diagnosis and Therapy.Bioinorganic chemistry and applications · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGold nanoparticles (GNPs) are receiving increasing attention as drug delivery carriers due to their high surface-to-volume ratio, hydrophilicity, and functionality. Drug delivery by nanocarriers has the potential to bypass P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) by altering the drug internalization mechanism and/or intracellular release pattern, inhibiting the activity of ABC-transporter efflux pumps, or downregulating the expression of genes responsible for the activity of efflux pumps.
objectiveWe developed a folate-gold-bilirubin (FGB) nanoconjugate to reverse MDR in P-expressing KB-Ch
methodsThe P-gp overexpressing KB-Ch
resultsThe FGB nanoconjugate was found to be a stronger inhibitor of the viability of multidrug-resistant KB-Ch
conclusionFGB nanoparticles significantly inhibit tumor growth, probably through the folate receptor, which is highly expressed in KB cells. Hence, folate-gold-bilirubin nanoparticles could be a promising agent for inducing apoptosis in P-gp-overexpressing drug-resistant cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.